cas 1571103-88-2|| where to buy 12,15-Dioxa-2,7,9-triazaheptadecanamide, 17-amino-N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-8-oxo-, hydrochloride (1:2)

Nom du produit:12,15-Dioxa-2,7,9-triazaheptadecanamide, 17-amino-N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-8-oxo-, hydrochloride (1:2)

IUPAC Name:3-{2-[2-(2-aminoethoxy)ethoxy]ethyl}-1-{4-[({2-[2-(2-aminoethoxy)ethoxy]ethyl}carbamoyl)amino]butyl}urea dihydrochloride

: CAS：1571103-88-2; Formule moléculaire：C18H42Cl2N6O6; Pureté：95%+

Unité d'emballage	Stock disponible	Prix($)
CM454250-100mg	in stock	řƩ
CM454250-250mg	in stock	ƩƩǎ
CM454250-1g	in stock	ĜǭŽ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1571103-88-2 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1571103-88-2; Formule moléculaire:C18H42Cl2N6O6; Point de fusion:-; Code SMILES:Cl.Cl.NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCN; Densité:

: Numéro de catalogue:CM454250; Poids moléculaire:509.47; Point d'ébullition:; N° Mdl:MFCD29035188; Stockage:

: Tenapanor; FDA has approved XPHOZAH (tenapanor), the first and only phosphate absorption inhibitor, indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

XPHOZAH, with its unique blocking mechanism of action, acts locally in the gut to inhibit the sodium hydrogen exchanger 3 (NHE3), reducing phosphate absorption through the paracellular pathway, the primary pathway of phosphate absorption.